Lyell Immunopharma News

Lyell Immunopharma | 8-K: Current report

Dec 11 01:22

Lyell Immunopharma | 424B5: Prospectus

Dec 9 21:41

Lyell Immunopharma | EFFECT: Others

Dec 6 19:05

Lyell Immunopharma | S-3: Registration statement for specified transactions by certain issuers

Nov 30 05:24

Lyell Immunopharma | 8-K: Current report

Nov 27 05:08

Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(3.93%)

Nov 13 05:12

Lyell Immunopharma | 10-Q: Q3 2024 Earnings Report

Nov 8 05:26

Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Nov 8 05:14

Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(3.93%)

Nov 5 02:34

Lyell Immunopharma | 3: Initial statement of beneficial ownership of securities-Director Ramachandra Sumant

Nov 2 04:58

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Ramachandra Sumant

Nov 2 04:57

Lyell Immunopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-James Tananbaum (“Tananbaum”)(5.3%),Foresite Capital Fund IV, L.P. (“FCF IV”)(3.2%), etc.

Nov 1 06:00

Lyell Immunopharma | 8-K: Current report

Nov 1 04:50

Lyell Immunopharma | 8-K: Current report

Oct 25 04:10

Lyell Immunopharma | 10-Q: Q2 2024 Earnings Report

Aug 8 10:19

Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Aug 8 04:13

Lyell Immunopharma | 8-K: Current report

Jun 26 20:38

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director NELSEN ROBERT

Jun 18 04:45

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Klausner Richard

Jun 18 04:24

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar

Jun 18 04:23